OliX

팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website.Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

form mail list
Name *
Tel *	- -
E-mail *	@
Subject *
Contents
File1
File2
Spam Check*	* 왼쪽의 자동등록방지 코드를 입력하세요.

Consent to Collect and Use Personal Information

I agree to the use of personal information collected from myself or other legitimate sources.

Information collected : Name, Phone number, E-mail, Message
Purpose of collection and use : conducting certain services or activities including but not limited to replying to inquiries and maintaining business records.
Period of retention and use : Personal information is to be discarded after the purpose of collection and use has been achieved.

- Personal Information shall be discarded without delay once the purpose of collection and use has been achieved; provided however that, if an obligation to retain such information exists under applicable law(s), the information shall be retained for a period of time as required by such law(s).
- Even prior to the purpose of use and collection being achieved, personal information may be discarded upon request via email sent to olixpharma@olixpharma.com. Please note, however, that your use of the services herein may be limited.

※ You have the right not to consent to the collection and use of your personal information, in which event your use of the services may be limited.

I agree to the terms and conditions.

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

Business Management

Purchasing

General Affairs

Facility Management

Contingency Planning

Planning

Budget/Performance Management

Mid to Long-term Business Goals/Strategy Planning

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Human Resources

HR Policy/System Establishment, Organization/Job Design

Recruitment/HR Management

Performance Management, Employee Welfare

HR Development

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Business Development

Develop/Maintain Client Relationships

Execute Licensing Agreements

New Business/Strategy Planning

Communications

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

Home
IR

IR

Financial Information

Financial Information

2023-12-05 13:39:27

· Statement of financial (Unit : One)

Category	2022	2021	2020
CurrentAssets	65,045,503,731	52,239,572,048	69,046,816,041
NoncurrentAssets	67,605,976,119	34,432,402,289	9,530,549,562
Assets	132,651,479,850	86,671,974,337	78,577,365,603
CurrentLiabilities	39,543,151,650	40,365,162,166	4,488,211,117
NoncurrentLiabilities	26,905,773,653	26,899,429,829	28,738,303,525
Liabilities	66,448,925,303	67,264,591,995	33,226,514,642
IssuedCapital	8,351,584,000	6,851,580,000	6,771,030,000
CapitalSurplus	(103,224,152,270)	(84,302,561,559)	(54,378,579,028)
Equity	66,202,554,547	19,407,382,342	45,350,850,961

· Income statement (Unit : One)

Category	2022	2021	2020
OperatingIncomeLoss	(22,375,609,579)	(24,228,556,815)	(16,241,420,668)
ProfitLossBeforeTax	(29,107,615,458)	(29,997,295,743)	(20,511,040,753)
ProfitLoss	(21,887,805,751)	(30,277,900,848)	(19,384,552,650)

2023-12-05 13:39:27

· Statement of financial (Unit : One)

Category	2022	2021	2020
CurrentAssets	(21,887,805,751)	(30,277,900,848)	(19,384,552,650)
NoncurrentAssets	62,003,630,101	45,090,673,748	67,801,086,830
Assets	68,714,095,252	39,903,491,992	14,367,906,390
CurrentLiabilities	130,717,725,353	84,994,165,740	82,168,993,220
NoncurrentLiabilities	40,059,991,029	37,587,645,282	4,929,840,730
Liabilities	23,128,539,544	26,573,411,821	28,665,896,657
IssuedCapital	63,188,530,573	64,161,057,103	33,595,737,387
CapitalSurplus	8,351,584,000	6,851,580,000	6,771,030,000
Equity	(100,818,776,997)	(81,386,343,214)	(51,119,486,358)

· Income statement (Unit : One)

Category	2022	2021	2020
OperatingIncomeLoss	67,529,194,780	20,833,108,637	48,573,255,833
ProfitLossBeforeTax	(22,649,809,817)	(24,939,613,262)	(14,776,640,712)
ProfitLoss	(21,082,020,094)	(30,879,075,917)	(19,043,658,792)